Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Type I interferon responses of bone cells to Staphylococcus aureus: A pilot study

Award Number: R03AI176300
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/13/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

Type I interferon responses of bone cells to Staphylococcus aureus: A pilot study - PROJECT SUMMARY Bone disorders such as osteomyelitis that result from bacterial infection are associated with severe inflammation and progressive bone loss. Staphylococcus aureus is the most common causative agent of osteomyelitis and the incidence and severity of staphylococcal osteomyelitis appears to be increasing despite improvements in prophylaxis and diagnosis. Dysregulation of osteoclast formation and activity results in bone destruction and/or abnormal bone remodeling at sites of infection, and osteoblasts play an essential role in the regulation of these bone-resorbing cells. In addition, bacterially infected osteoblasts and osteoclasts are capable of producing an array of immune mediators that could promote the recruitment and activation of inflammatory leukocytes in bone tissue. While type I interferons, such as IFN-a and IFN-b, are best known for their antiviral effects, it is becoming increasingly apparent that they can impact susceptibility to bacterial pathogens including S. aureus. Furthermore, IFN-a and IFN-b have been shown to affect bone homeostasis and are potent inhibitors of osteoclastogenesis. We have intriguing preliminary data indicating that osteoblasts express IFN-b, select IFN-stimulated genes, and key intracellular mediators of interferon effects, in response to S. aureus infection. In this R03 pilot project, we will begin to test the hypothesis that S. aureus infected bone cells are a significant source of type I interferons and that such production serves to limit the intracellular bacterial burden and/ or pro-osteoclastogenic responses associated with conditions such as osteomyelitis. We will characterize the type I interferon responses of isolated bone cells to S. aureus infection and perform an initial determination of the effects of IFN-a and IFN-b on bacterial burden and bone cell formation and function in S. aureus-infected osteoblasts and osteoclasts. These studies will provide critical preliminary data for future studies to fully define the role played by type I interferons in such infections for which R01 mechanism support will be sought.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$267 )
2026	2025	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	2	3/4/2026	NON-COMPETING CONTINUATION	-$267
														Subtotal = -$267

Issue Date FY: 2025 ( Subtotal = $70,337 )
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	2	10/25/2024	NON-COMPETING CONTINUATION	$70,337
														Subtotal = $70,337

Issue Date FY: 2024 ( Subtotal = $72,512 )
2024	2024	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	1	11/13/2023	NEW	$65,261
2024	2024	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	001	1	9/11/2024	NEW	$7,251
														Subtotal = $72,512

Grand Total All Awards = $142,582

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Type I interferon responses of bone cells to Staphylococcus aureus: A pilot study

Award Number: R03AI176300

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/13/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer